Press releaseGlobe Newswire
Cingulate
CINGW · NASDAQ
$0.0033−$0.0068 (−67.33%)TodayMarket closed ·
Prev close $0.0101
Latest news
- Press releaseGlobe Newswire
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
- Press releaseGlobe Newswire
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
- Press releaseGlobe Newswire
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
- Press releaseGlobe Newswire
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
- Press releaseGlobe Newswire
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- Press releaseGlobe Newswire
Cingulate Receives Complete Response Letter from FDA for CTx-1301
- Press releaseGlobe Newswire
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- Press releaseGlobe Newswire
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
- Press releaseGlobe Newswire
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.